Drug utilisation trends in a physical rehabilitation hospital

Gordana M. Ljubojević; Milan  Mastikosa; Tanja  Dostanić Došenović; Snježana  Novaković Bursać; Nataša  Tomić; Goran  Talić; Ranko  Škrbić; Miloš P.  Stojiljković

doi:10.2298/VSP180118046L

Gordana M. Ljubojević Institute of Physical Medicine and Rehabilitation “Dr Miroslav Zotović” Banja Luka, Hospital Pharmacy Department, Banja Luka, Republic of Srpska, Bosnia and Herzegovina
Milan Mastikosa Institute of Physical Medicine and Rehabilitation “Dr Miroslav Zotović” Banja Luka, Hospital Pharmacy Department, Banja Luka, Republic of Srpska, Bosnia and Herzegovina
Tanja Dostanić Došenović Institute of Physical Medicine and Rehabilitation “Dr Miroslav Zotović” Banja Luka, Hospital Pharmacy Department, Banja Luka, Republic of Srpska, Bosnia and Herzegovina
Snježana Novaković Bursać Institute of Physical Medicine and Rehabilitation “Dr Miroslav Zotović” Banja Luka, Department of Physical Rehabilitation, Banja Luka, Republic of Srpska, Bosnia and Herzegovina
Nataša Tomić Institute of Physical Medicine and Rehabilitation “Dr Miroslav Zotović” Banja Luka, Department of Physical Rehabilitation, Banja Luka, Republic of Srpska, Bosnia and Herzegovina
Goran Talić Institute of Physical Medicine and Rehabilitation “Dr Miroslav Zotović” Banja Luka, Department of Orthopaedic Surgery, Banja Luka, Republic of Srpska, Bosnia and Herzegovina
Ranko Škrbić University of Banja Luka, Faculty of Medicine, Department of Basic & Clinical Pharmacology, Banja Luka, Republic of Srpska, Bosnia and Herzegovina
Miloš P. Stojiljković University of Banja Luka, Faculty of Medicine, Department of Basic & Clinical Pharmacology, Banja Luka, Republic of Srpska, Bosnia and Herzegovina

DOI: https://doi.org/10.2298/VSP180118046L

Keywords: hospitals, physical and rehabilitation medicine, drug therapy, drug utilisation

Abstract

Abstract

Background/Aim. Drug utilisation monitoring could identify drug-related problems and hence improve the awareness of irrational drug use. The objective of this study was to analyse the drug utilisation patterns in a rehabilitation hospital over the period 2011–2016. Methods. The Anatomic Therapeutic Chemical classification/Defined Daily Dose (ATC/DDD) methodology was used to monitor the drug utilisation expressed as a number of DDD per 100 patient-days (HPD). The values of DDDs were obtained from the World Health Organisation (WHO) Collaborating Centre for Drug Statistics Methodology. Utilisation trends were analysed by means of the Compound Aggregate Growth Rate (CAGR), which is defined as an average annual change rate of some value during the period of interest. Results. The number of patient-days increased during the six years period; the CAGR being1.8% annually. At the same time, the total number of dispensed DDDs as well as the number of DDD/HPD decreased with the CAGR of -2.0% and -3.7% respectively. The average drug cost per patient-day varied from BAM 1.38 in 2013 to 0.95 in 2016; the CAGR being -1.8%. The most utilised drugs belonged to the ATC groups C, A, B, M and N and they contributed to an average of 77% of all drugs used each year. On the top of the list of most utilised drugs were: hydroxocobalamin, thioctic acid, enalapril, diclofenac, amlodipine, acetylsalicylic acid, pantoprazole, paracetamol and bromazepam. Conclusions. The overall drug utilisation in the hospital was modest and almost equal in 2016 compared to 2011. Besides the leading consumption of vitamin B12 and thioctic acid, this study points out some interesting prescribing patterns, such as predominant use of diclofenac over ibuprofen, and overuse of proton pump inhibitors. There is a need for educative interventions among physicians in order to improve their prescribing practice.

References

REFERENCES

Strom BL. Pharmacoepidemiology. 4th ed. Chichester, UK: John Wiley and Sons; 2006.

World Health Organization. Introduction to Drug Utilization Research. Oslo. 2003. Available from: http://apps.who.int/medicinedocs/pdf/s4876e/s4876e.pdf. [accessed 2017 March 27].

Zuppa A, Vijayakumar S, Jayaraman B, Patel D, Narayan M, Vi-jayakumar K, et al. An informatics approach to assess pediatric pharmacotherapy: design and implementation of a hospital drug utilization system. J Clin Pharmacol 2007; 47(9): 1172–80.

Wettermark B, Elseviers M, Almarsdóttir AB, Andersen M, Benko R, Bennie M, et al. Introduction to drug utilization re-search. In: Elseviers M, Wettermark B, Almarsdottir AB, An-dersen M, Benko R, Bennie M, et al, editors. Drug Utilization Research: Methods and Applications. Chichester: John Wiley & Sons; 2016. p. 1–12.

Jhaveri BN, Patel TK, Barvaliya MJ, Tripathi CB. Drug utilization pattern and pharmacoeconomic analysis in geriatric medical in-patients of a tertiary care hospital of India. J Pharmacol Pharmacother 2014; 5(1): 15–20.

Chatterjee S, Mandal A, Lyle N, Mukherjee S, Singh AK. Drug utilization study in a neonatology unit of a tertiary care hospital in eastern India. Pharmacoepidemiol Drug Saf 2007; 16(10): 1141–5.

Sequi M, Campi R, Clavenna A, Bonati M. Methods in pharma-coepidemiology: a review of statistical analyses and data re-porting in pediatric drug utilization studies. Eur J Clin Phar-macol 2013; 69(3): 599–604.

Janković S, Đukić-Dejanović S. Drug utilization trends in Clinical hospital centre 'Kragujevac' from 1997-1999. Ind J Pharmacol 200; 33: 29–36.

Marković-Peković V, Škrbić R. Long-term drug use and poly-pharmacy among the elderly population in the Republic of Srpska, Bosnia and Herzegovina. Vojnosanit Pregl 2016; 73(5): 435–41.

Marković-Peković V, Škrbić R, Petrović A, Vlahović-Palčevski V, Mrak J, Bennie M, et al. Polypharmacy among the elderly in the Republic of Srpska: extent and implications for the future. Expert Rev Pharmacoecon Outcomes Res 2016; 16(5): 609–18.

Marković-Peković V, Škrbić R, Godman B, Gustafsson LL. Ongo-ing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. Expert Rev Phar-macoecon Outcomes Res 2012; 12(5): 661–71.

Marković-Peković V, Stoisavljević-Šatara S, Škrbić R. Outpatient utilization of drugs acting on nervous system: a study from the Republic of Srpska, Bosnia & Herzegovina. Eur J Clin Phar-macol 2010; 66(2): 177–86.

Marković-Peković V, Stoisavljević-Šatara S, Škrbić R. Utilisation of cardiovascular medicines in Republic of Srpska, Bosnia and Herzegovina, 5 years study. Pharmacoepidemiol Drug Saf 2009; 18(4): 320–6.

WHO Collaborating Centre for Drug Statistics Methodology. Guide-lines for ATC classification and DDD assignment 2017. Oslo; 2016. 20th ed. Available from: https://www.whocc.no/ fi-learchive/publications/2017_guidelines_web.pdf. [accessed 2017 March 28].

Škrbić R, Babić-Đurić D, Stoisavljević-Šatara S, Stojaković N, Nežić L. The role of drug donations on hospital use of antibiotics during the war and postwar period. Int J Risk Safety Med 2001; 14(1–2): 31–40.

Compound Aggregate Growth Rate - CAGR. Available from: http://www.investopedia.com /terms/c/cagr.asp [accessed 2017 July 27].

Rajarathna K, Vishwanath M, Ramaswamy AD, Kamath SD, Sukritha S, Hosthota A, et al. Evaluation of WHO prescribing indicators among orthopaedic inpatients at tertiary care hospital. J Chem Pharm Res 2014; 6(8): 278–80.

Godman B, Wettermark B, van Woerkom M, Fraeyman J, Alvarez-Madrazo S, Berg C, et al. Multiple policies to enhance prescrib-ing efficiency for established medicines in Europe with a par-ticular focus on demand-side measures: findings and future implications. Front Pharmacol 2014; 5: 106.

Goldberg H, Mibielli MA, Nunes CP, Goldberg SW, Buchman L, Mezitis SG,et al. A double-blind, randomized, comparative study of the use of a combination of uridine triphosphate tri-sodium, cytidine monophosphate disodium, and hydroxocoba-lamin, versus isolated treatment with hydroxocobalamin, in patients presenting with compressive neuralgias. J Pain Res 2017; 10: 397–404.

Smelt HJM, Pouwels S, Smulders JF. Different Supplementation Regimes to Treat Perioperative Vitamin B12 Deficiencies in Bariatric Surgery: a Systematic Review. Obes Surg 2017; 27(1): 254–62.

Brayfield A. Hydroxocobalamin. In: Brayfield A, edi-tor.Martindale: The Complete Drug Reference. 8th ed. Lon-don, UK: PhP, Pharmaceutical Press, 2014.

Kennedy DO. B Vitamins and the Brain: Mechanisms, Dose and Efficacy-A Review. Nutrients 2016; 8(2): 68.

Mauro GL, Martorana U, Cataldo P, Brancato G, Letizia G. Vita-min B12 in low back pain: a randomised, double-blind, place-bo-controlled study. Eur Rev Med Pharmacol Sci 2000; 4(3): 53–8.

Chiu CK, Low TH, Tey YS, Singh VA, Shong HK. The efficacy and safety of intramuscular injections of methylcobalamin in patients with chronic nonspecific low back pain: a randomised controlled trial. Singapore Med J 2011; 52(12): 868–73.

Garcia-Alcala H, Santos Vichido CI, Islas Macedo S, Genestier-Tamborero CN,Minutti-Palacios M, Hirales Tamez O, et al. Treat-ment with α-Lipoic Acid over 16 Weeks in Type 2 Diabetic Patients with Symptomatic Polyneuropathy Who Responded to Initial 4-Week High-Dose Loading. J Diabetes Res 2015; 2015: 189857.

Ziegler D, Low PA, Freeman R, Tritschler H, Vinik AI. Predictors of improvement and progression of diabetic polyneuropathy following treatment with α-lipoic acid for 4years in the NATHAN 1 trial. J Diabetes Complications 2016; 30(2): 350–6.

Lei H, Gao Q, Liu S, Xu J. The Benefit and Safety of Aspirin for Primary Prevention of Ischemic Stroke: A Meta-Analysis of Randomized Trials. Front Pharmacol 2016; 7: 440.

Elwood PC, Morgan G, Galante J, Chia JWK, Dolwani S, Graziano JM, Steward W. Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointes-tinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased Risk. PLoS One 2016; 11(11): e0166166.

Lanza FL, Chan FKL, Quigley EM. Guidelines for Prevention of NSAID-Related Ulcer Complications. Am J Gastroenterol 2009; 104(3): 728–38.

Manohar V, Vinay M, Jayasree T, Kishan P, Ubedulla S, Dixit R. Prescribing pattern of gastroprotective agents with non-steroidal anti-inflammatory drugs. J Pharmacol Pharmacother 2013; 4(1): 59–60.

Eusebi LH, Rabitti S, Artesiani ML, Gelli D, Montagnani M, Zagari RM, et a. Proton pump inhibitors: Risks of long-term use. J Gastroenterol Hepatol 2017; 32(7): 1295–302.

Krum H, Swergold G, Gammaitoni A, Peloso PM, Smugar SS, Curtis SP, et al. Blood Pressure and Cardiovascular Outcomes in Patients Taking Nonsteroidal Antiinflammatory Drugs. Cardiovasc Ther 2011; 30(6): 342–50.

European Medicine Agency. New safety advice for diclofenac. EMA. 2013. Available from: http:

//www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Diclofenac-containing medicin-al_products/European_Commission_final_decision/WC500155819.pdf. [accessed 2017 August 31].

Cosano G, Giangreco M, Ussai S, Giorgini T, Biasutti E, Barbone F, et al. Polypharmacy and the use of medications in inpatients with acquired brain injury during post-acute rehabilitation: A cross-sectional study. Brain Inj 2016; 30(3): 353–62.

Binder A, Baron R. The Pharmacological Therapy of Chronic Neuropathic Pain. Dtsch Arztebl Int 2016; 113(37): 616–25.

Lima M, Farage L, Cury M, Bahamad F. Update on Middle Ear Barotrauma after Hyperbaric Oxygen Therapy – Insights on Pathophysiology. Int Arch Otorhinolaryngol 2014; 18(2): 204–9.

Yamamoto Y, Noguchi Y, Enomoto M, Yagishita K, Kitamura K. Otological complications associated with hyperbaric oxygen therapy. Eur Arch Otorhinolaryngol 2016; 273(9): 2487–93.

Capes JP, Tomaszewski C. Prophylaxis against middle ear baro-trauma in US hyperbaric oxygen therapy centers. Am J Emerg Med 1996; 14(7): 645–8.

Müller-Pebody B, Muscat M, Pelle B, Klein BM, Brandt CT, Monnet DL. Increase and change in pattern of hospital antimicrobial use, Denmark, 1997–2001. J Antimicrob Chemother 2004; 54(6): 1122–6.

-26.